Evidence map›Paper›PMID 41506791›Full record

ArticleJournal for immunotherapy of cancer2026

CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation.

Sara A Murphy, Jiaqi Li, Upasana Sahu, Jessica Swanner, Cole T Lewis, Benedict Anchang, Yan Cui, E Antonio Chiocca, Balveen Kaur

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sara A MurphyGraduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, Texas, USA.
Jiaqi LiBiostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.
Upasana SahuPathology, Augusta University Medical College of Georgia, Augusta, Georgia, USA.
Jessica SwannerNeurosurgery, The University of Texas Health Science Center, Houston, Texas, USA.
Cole T LewisNeurosurgery, LSU Health New Orleans, New Orleans, Louisiana, USA.
Benedict AnchangBiostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.
Yan CuiBiochemistry & Molecular Biology, Augusta University Medical College of Georgia, Augusta, Georgia, USA.
E Antonio ChioccaNeurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Balveen KaurPathology, Augusta University Medical College of Georgia, Augusta, Georgia, USA bkaur@augusta.edu.ORCID http://orcid.org/0000-0001-7738-0804

Funding

Targeting the CD73-adenosinergic pathway in head and neck cancerR01DE032178 · NIDCR · AUGUSTA UNIVERSITY · PI YAN CUI · 2023 to 2026
$2.7M
NIDCR NIH HHS R01 DE032178
6 · The paper itself

Abstract

backgroundOncolytic herpes simplex virus (oHSV) therapy is a live virus-based immunotherapy that lyses tumor cells which release antigens and activate antitumor immunity. oHSV therapy has been shown to increase ATP production and release of extracellular ATP (eATP). In the extracellular tumor microenvironment, eATP functions as an immune-activating damage-associated molecular pattern but is hydrolyzed to extracellular adenosine (eADO), which can be immune-suppressive. eADO is generated by the sequential action of ectoenzymes CD39 and CD73 (

methodsWe evaluated changes in eADO signaling in vitro and in patient specimens after virotherapy. A genetic CD73 knock-out mouse model and blocking antibodies were used to assess the impact of CD73 on virotherapy in two different solid tumor models. Single-cell RNA sequencing was employed to assess changes in immune cell infiltration and communication. Flow cytometric immunophenotyping and immunofluorescent imaging were utilized to confirm single-cell sequencing predicted changes in tumor microenvironment.

resultsTranscriptomic analysis of patient tumors pre-virotherapy and post-virotherapy with CAN-3110 revealed increased expression of the adenosine receptor gene

conclusionsHere, we identify that immunosuppressive eADO signaling in the TME is a major barrier to oHSV therapy and CD73 blockade prevents tumor immune escape. The combination of oHSV with CD73 blockade supports the development of an antitumor immune memory response in solid tumors. This study supports clinical development of this combination strategy.

Indexed as

5'-NucleotidaseAntigen PresentationMacrophagesNeoplasmsOncolytic VirotherapyOncolytic VirusesSimplexvirusAnimalsCell Line, TumorFemaleGPI-Linked ProteinsHumansImmunotherapyMiceMice, KnockoutTumor Microenvironment5'-NucleotidaseGPI-Linked ProteinsNT5E protein, humanCombination therapyImmunotherapyOncolytic virusSolid tumorTumor microenvironment - TME

Identifiers

PMID41506791
PMCPMC13059893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.